Peptidic regulation of heart rate and interactions with the autonomic nervous system

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 578-585

  Beaulieu, Pierre ^a   Lambert, Chantal ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Autonomic nervous system; Endothelium; Heart rate; Neuromodulation; Neuropeptides; Peptides

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BOMBESIN; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; DYNORPHIN; ENDOTHELIN; ENKEPHALIN; GALANIN; GASTRIN; GLUCAGON; NATRIURETIC PEPTIDE TYPE C; NEUROHORMONE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTRANSMITTER; SOMATOSTATIN; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

AUTONOMIC NERVOUS SYSTEM; CELL COMMUNICATION; HEART CONDUCTION; HEART FUNCTION; HEART RATE; NEUROMODULATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SINUS NODE;

AUTONOMIC NERVOUS SYSTEM; HEART CONDUCTION SYSTEM; HEART DISEASES; HEART RATE; HUMANS; MODELS, CARDIOVASCULAR; NEUROPEPTIDES;

EID: 0032029142     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00305-2     Document Type: Review

References (69)

1. [1] Moorman AFM, Lamers WH. A molecular approach towards the understanding of early heart development: an emerging synthesis. In: E Haj, editors. Molecular biology of the muscle. Colchester, UK: Portland, 1992:285-300.
2. [2] Gorza L, Vettore S, Vitadello M. Molecular and cellular diversity of heart conduction system myocytes. Trends Cardiovasc Med 1994;4:153-159.
3. [3] Bloom FE. Neurotransmission and the central nervous system. In: Hardman, JG, Goodman Gilman A, Limbird LE, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:267-293.
4. [4] Hökfelt T, Elfvin LG, Elde R, Schultzberg M, Goldstein M, Luft R. Occurrence of somatostatin-like immunoreactivity in some peripheral sympathetic noradrenergic neurons. Proc Natl Acad Sci USA 1977;74:3587-3591.
5. [5] Steele PA, Choate JK. Innervation of the pacemaker in guinea-pig sinoatrial node. J Auton Nerv Syst 1994;47:177-187.
6. [6] Steele PA, Gibbins IL, Morris JL. Projections of intrinsic cardiac neurons to different targets in the guinea-pig heart. J Auton Nerv Syst 1996;56:191-200.
7. [7] Weihe E, Reinecke M. Peptidergic innervation of the mammalian sinus nodes: vasoactive intestinal polypeptide, neurotensin, substance P. Neurosci Lett 1981;26:283-288.
8. [8] Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996;48:113-178.
9. [9] Zupanc GKH. Peptidergic transmission: from morphological correlates to functional implications. Micron 1996;27:35-91.
10. [10] Hökfelt T, Millhorn D, Seroogy K, Tsuruo Y, Ceccatelli S, Lindh B, Meister B, Melander T, Schalling M, Bartfai T. Coexistence of peptides with classical neurotransmitiers. Experientia 1987;43:768-780.
11. [11] Shah AM. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res 1996;31:847-867.
12. [12] Marron K, Wharton J, Sheppard MN, Gulbenkian S, Royston D, Yacoub MH, Anderson RH, Polak JM. Human endocardial innervation and its relationship to the endothelium: an immunohistochemical, histochemical, and quantitative study. Cardiovasc Res 1994;28:1490-1499.
13. [13] Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 1982;79:5485-5489.
14. [14] Gu J, Polak JM, Allen JM, Huang WM, Sheppard MN, Tatemoto K, Bloom SR. High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart. J Histochem Cytochem 1984;32:467-472.
15. [15] Forsgren S. Neuropeptide Y-like immunoreactivity in relation to the distribution of sympathetic nerve fibres in the heart conduction system. J Mol Cell Cardiol 1989;21:279-290.
16. [16] Balasubramaniam A, Sherrif S, Rigel DF, Fisher JE. Characterization of neuropeptide Y binding sites in rat cardiac ventricular membranes. Peptides 1990;11:545-550.
17. [17] Franco-Cereceda A, Lundberg JM. Potent effects of neuropeptide Y and calcitonin generelated peptide on human coronary vascular tone in vitro. Acta Physiol Scand 1987;131:159-160.
18. [18] Said SI, Mutt V. Polypeptide with broad biological activity. Isolation from small intestine. Science 1970;169:1217-1218.
19. [19] Rigel DF, Lathrop DA. Vasoactive intestinal peptide facilitates atrioventricular nodal conduction and shortens atrial and ventricular refractory periods in conscious and anaesthetised dogs. Circ Res 1990;67:1323-1333.
20. [20] Franco-Cereceda A, Bengtsson L, Lundberg JM. Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal peptide and somatostatin on the human right atrium in vitro. Eur J Pharmacol 1987;134:69-76.
21. [21] Rigel DF. Effects of neuropeptides on heart rate in dogs: comparison of VIP, PHI, NPY, CGRP, and NT. Am J Physiol 1988;255:H311-H317.
22. [22] Alter WA III, Weiss GK, Priola DV. Vagally induced tachycardia in atropinised dogs: effects of β-adrenergic blockade. Eur J Pharmacol 1973;24:329-333.
23. [23] Taton G, Chatelain P, Delhaye M, Camus JC, De Neef P, Waelbroeck M, Tatemoto K, Robberecht P, Christophe J. Vasoactive intestinal peptide (VIP) and peptide having N-terminal isoleucine amide (PHI) stimulate adenylate cyclase activity in human heart membranes. Peptides 1982;3:897-900.
24. [24] Saito A, Kimura S, Goto K. Calcitonin gene-related peptide as potential neurotransmitter in guinea-pig right atrium. Am J Physiol 1986;250:H693-H698.
25. [25] Bell D, McDermott BJ. Calcitonin gene-related peptide in the cardiovascular system: Characterization of receptor populations and their (patho)physiological significance. Pharmacol Rev 1996;48:253-288.
26. [26] Xi X, Duff MJ, Weber M, Fiscus RR, Thomas JX, O'Toole MF, Randall WC, Wurster RD. In vivo effects of calcitonin gene-related peptide (CGRP) on intracardiac vagal ganglia. FASEB J 1989;3:A413.
27. [27] Hoover DB, Hancock JC. Distribution of substance P binding site in guinea-pig heart and pharmacological effects of substance P. J Auton Nerv Syst 1988;23:189-197.
28. [28] Corr L. Neuropeptides and the conduction system of the heart. Int J Cardiol 1992;35:1-12.
29. [29] Saito K, Gutkind JS, Saavedra JM. Angiotensin II binding sites in the conduction system of rat hearts. Am J Physiol 1987;253:H1618-H1622.
30. [30] Kobayashi M, Furukawa Y, Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol 1978;50:17-25.
31. [31] Lambert C, Godin D, Fortier P, Nadeau R. Direct effects in vivo of angiotensins I and II on the canine sinus node. Can J Physiol Pharmacol 1991;69:389-392.
32. [32] Lambert C. Mechanisms of angiotensin II chronotropic effect in anaesthetized dogs. Br J Pharmacol 1995;115:795-800.
33. 1 receptors in the rat heart conduction system. Eur J Pharmacol 1993;235:301-303.
34. [34] de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981;28:89-94.
35. [35] Cantin M, Thibault G, Haile-Meskel H, Ding J, Milne RW, Ballak M, Charbonneau C, Nemer M, Drouin J, Garcia R, Genest J. Atrial natriuretic factor in the impulse-conduction system of rat cardiac ventricles. Cell Tissue Res 1989;256:309-325.
36. [36] Schiebinger RJ, Linden J. Effect of atrial contraction frequency on atrial natriuretic peptide secretion. Am J Physiol 1986;251:H1095-1099.
37. [37] Baum T, Sybertz EJ, Watkins RW, Nelson S, Coleman W, Pula KK, Prioli N, Rivelli M, Grossman A. Hemodynamic actions of a synthetic atrial natriuretic factor. J Cardiovasc Pharmacol 1986;8:898-905.
38. [38] Sasaki A, Kida O, Kangawa K, Matsuo H, Tanaka K. Involvement of sympathetic nerves in cardiosuppressive effects of α-human atrial natriuretic polypeptide (α-hANP) in anaesthetized rats. Eur J Pharmacol 1986;20:345-349.
39. [39] Zeuzem S, Olbrich HG, Haak T, Jungmann E. In vivo evidence that human atrial natriuretic factor-(99-126) (hANF) stimulates parasympathetic activity in man. Eur J Clin Pharmacol 1990;39:77-79.
40. [40] Atchison DJ, Ackermann U. The interaction between atrial natriuretic peptide and cardiac parasympathetic function. J Auton Nerv Syst 1993;42:81-88.
41. [41] Lambert C, Ribuot C, Robichaud A, Cusson JR. Negative chronotropic effect of the atrial natriuretic peptide in an anaesthetized dog model. Eur J Pharmacol 1994;252:245-252.
42. [42] Gisbert M-P, Fischmeister R. Atrial natriuretic factor regulates the calcium current in frog isolated cardiac cells. Circ Res 1988;62:660-667.
43. [43] Beaulieu P, Cardinal R, De Lean R, Lambert C. Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs. Br J Pharmacol 1996;118:1790-1796.
44. [44] Mukaddam-Daher S, Lambert C, Gutkowska J. Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Hypertension 1997;30:83-87.
45. [45] Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
46. [46] Hansson M, Forsgren S. Immunoreactive atrial and brain natriuretic peptides are co-localized in Purkinje fibres but not in the innervation of the bovine heart conduction system. Histochem J 1995;27:222-230.
47. [47] Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-870.
48. [48] Espiner EA. Physiology of natriuretic peptides. J Intern Med 1994;235:527-541.
49. [49] Beaulieu P, Cardinal R, Francoeur F, Tremblay J, Lambert C. Characterization of C-type natriuretic peptide chronotropic effect. Circulation 1996;94:I-715. Suppl.
50. [50] Beaulieu P, Cardinal R, Page P, Francoeur F, Tremblay J, Lambert C. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol 1997;273 (in press).
51. [51] Lin X, Hanze J, Heese F, Sodmann R, Lang RE. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 1995;77:750-758.
52. [52] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
53. [53] Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflügers Arch 1988;413:108-110.
54. [54] Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. The positive inotropic action of a novel endothelium-derived vasoconstrictor peptide, endothelin, on guinea-pig atria. Am J Physiol 1988;255:H970-H973.
55. A receptors in guinea pig atria. Circ Res 1995;76:284-292.
56. [56] Crozier IG, Richards AM, Foy SG, Ikram H. Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction in man. PACE 1993;16:738-742.
57. [57] Takata Y, Hirayama Y, Kiyomi S, Ogawa T, Iga K, Ishii T, Nagai Y, Ibukiyama C. The beneficial effects of atrial natriuretic peptide on arrhythmia's and myocardial high-energy phosphates after reperfusion. Cardiovasc Res 1996;32:286-293.
58. [58] Ikram H. The renin-angiotensin-aldosterone system and cardiac ischemia. Heart 1996;76:60-67.
59. [59] Webster MWI, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE. Effect of enalaprilat on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985;56:566-569.
60. [60] Salvati P, Chierchia S, Dho I, Ferrario RG, Parenti P, Vicedomini G, Patrono C. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol 1991;17:1007-1014.
61. [61] Pernow J, Wang Q-D. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997;33:518-526.
62. [62] Huang MH, Wolf SG, Armour JA. Ventricular arrhythmias induced by chemically modified intrinsic cardiac neurones. Cardiovasc Res 1994;28:636-642.
63. [63] Newby DE, Webb DJ. The endothelin system in cardiovascular disease. Br Med J 1997;314:531-532.
64. [64] Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei C-M, McKinley LJ, Burnett JC Jr.. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-2376.
65. [65] Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 1997;96:509-516.
66. [66] Richards AM. The natriuretic peptides and hypertension. J Intern Med 1994;235:543-560.
67. [67] Singer DRJ, Markandu ND, Buckley MG, Miller MA, Sagnella GA, Lachno DR, Cappuccio FP, Murday A, Yacoub MH, MacGregor GA. Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Circulation 1994;89:1153-1159.
68. [68] Fagard R, Macor F, Vanhaecke J. Signs of functional efferent reinnervation of the heart in patients after cardiac transplantation. Acta Cardiol 1995;5:369-380.
69. [69] Hunt RA, Ciuffo GM, Saavedra JM, Tucker DC. Sympathetic innervation modulates the expression of angiotensin II receptors in embryonic rat heart grafted in oculo. J Mol Cell Cardiol 1995;27:2445-2452.